A descriptive study of erythropoietin use and costs in hematologic patients;Estudio de utilización y descripción de costes de eritropoyetina en pacientes hematológicos

Farmacia Hospitalaria

Volumn 30, Issue 6, 2006, Pages 343-350

  Pelufo Pellicer, A ^a,c   Monte Boquet, E ^a   Poveda Andres J L ^a   Cuellar Monreal M J ^b  

^a HOSPITAL UNIVERSITARIO LA FE   (Spain)

^b HOSPITAL FRANCESC DE BORJA   (Spain)

^c NONE   (Spain)

Author keywords

Cost; Effectiveness; Epoetin; Erythropoietin; Hematology

Indexed keywords

ERYTHROPOIETIN;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG COST; DRUG EFFICACY; DRUG INDICATION; DRUG USE; FEMALE; FOLLOW UP; HUMAN; LYMPHOMA; MALE; MEDICAL SOCIETY; MULTIPLE MYELOMA; MYELODYSPLASTIC SYNDROME; PATIENT SELECTION; PRACTICE GUIDELINE; TREATMENT RESPONSE;

EID: 33846796257     PISSN: 11306343     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1130-6343(06)74005-3     Document Type: Article

References (26)

1. Miller CB, Jones RJ, Piantadosi S, Abeloff MD, Spivak JL. Decrease erythropoietin response in patients with the anemia of cancer. New Engl J Med 1990; 322: 1689-92.
2. Tchekmedyian NS. Anemia in cancer patients: Significance, epidemiology, and current therapy. Oncology (Williston Park) 2002; 16: 17-24.
3. Glaspy J, Degos L, Dicato M, Demetri GD. Comparable efficacy of epoetin alfa for anemic cancer patients receiving platinum and non-platinum based chemotherapy: A retrospective subanalysis of two large, community-based trials. Oncologist 2002; 7: 126-35.
4. Quirt I, Robenson C, Lau CY, Kovacs M, Burdette-Radoux S, Tang SC, et al. and the Canadian Eprex Oncology Study Group. Epoetin alfa therapy increases hemoglobin levels and improves quality of life in patients with cancer-related anemia who are not receiving chemotherapy and patients with anemia who receiving chemotherapy. J Clin Oncol 2001; 19: 4126-34.
5. Daneryd P. Epoetin alfa for protection of metabololic and exercise capacity in cancer patients. Semin Oncol 2002; 29: 69-74.
6. Ludwig H, Fritz E. Anemia in cancer patients. Semin Oncol 1998; 25: 2-6.
7. Grabilove JL, Cleeland CS, Livingston RB, Sarokhan B, Winer E, Einhorn LH. Clinical evaluation of once-weekly dosing of epoetin alfa in chemotherapy patients: Improvements in hemoglobin and quality of life similar to three-times-weekly dosing. J Clin Oncol 2001; 19: 2875-82.
8. Consejo General de Colegios Oficiales de Farmacéuticos. Catálogo de Especialidades Farmacéuticas, 2005.
9. Cella S, Dobrez D, Glaspy J. Control of cancer-related anemia with erythropoietic agents: A review of evidence for improved quality of life and clinical outcomes. Ann Oncol 2003; 14: 511-9.
10. Matchtay M, Pajak T, Suntharalingam M, Hershock D, Stripp D, Cmelak A, et al. Definitive radiotherapy +/- erythropoietin for squamous cell carcinoma of head and neck: Preliminary report of RTOG 99-03. Int J Radiat Oncol Biol Phys 2004; 60: S132.
11. Henke M, Laszig R, Rübe C, Dchafer U, Haase KD, Schilcher B, et al. Erythropoietin to treat head and neck cancer patients with anemia undergoing radiotherapy: Randomized, double-blind, placebo-controll trial. Lancet 2003; 362: 1255-60.
12. Leyland B. Breast cancer trial erythropoietin terminated unexpectedly. Lancet Oncil 2003; 4: 459-60.
13. Arcasoy MO, Amin K, Chou SC, Haroon Z, Varia M, Raleigh JA. Erythropoietin and erythropoietin receptor expression in head and neck cancer: Relationship to tumor hypoxia. Clin Cancer Res 2005; 11: 20-7.
14. Bokemayer C, Aapro MS, Courdi A, Foubert J, Link H, Österborg A, et al. EORTC guidelines for the use of erythropoietic proteins in anaemic patients with cancer. Eur J Can 2004; 40: 2201-16.
15. Clopés A, Mesía R. Factores estimulantes de eritropoyesis y anemia en pacientes con cáncer: los estudios indican prudencia [editorial]. Farm Hosp 2005; 29: 73-4.
16. Eprex®. [Ficha técnica del producto]. Laboratorios Janssen-Cilag, S.A. Última revisión: octubre de 2004.
17. Neorecormon®. [Ficha técnica del producto]. Laboratorio Roche Registration Ltd. Última revisión: mayo de 2004.
18. Rizzo JD, Lichtin AE, Woolf SH, Seidenfeld J, Bennet CL, Cella D, et al. Use of epoetin in patients with cancer: Evidence-based clinical practice guidelines of American Society of Clinical Oncology and American Society of Hematology. Blood 2002; 100: 2303-20. Also published as J Clin Oncol 2002; 20: 4083-107.
19. Bowen D, Culligan D, Jowitt S, Kelsey S, Mufti G, Oscier D, et al. Guidelines for the diagnosis and therapy of adult myelodysplastic syndromes. Br J Haematol 2003; 120: 187-200.
20. Márquez Saavedra E, Artacho Criado S. Estudio de utilización de eritropoyetina en el síndrome mielodisplá sico. Farm Hosp 2004; 28: 395-401.
21. Hellstrom-Lindberg E, Ahlgren T, Beguin Y, Carlsson M, Carneskog J, Dahl IM, et al. Treatment of anemia in myelodysplastic syndromes with granulocyte colony-stimulating factor plus erythropoietin: Results from a randomized phase II study and long-term follow-up of 71 patients. Blood 1998; 92: 68-75.
22. Cheson BD, Bennett JM, Kantarjian H, Pinto A, Schiffer CA, Nimer SD, et al. Report of an international working group to standardized response criteria for myelodysplastic syndromes. Blood 2000; 96: 3671-4.
23. Fernández Martín JM, Villa Rubio A, Cameán Fernández M, Borrero Rubio JM, Martínez Díaz C, Díaz Navarro J, et al. Eritropoyetina: Estudio de utilización en oncología. Farm Hosp 2004; 28: 20-8.
24. Osterborg A, Brandberg Y, Molostova V, Iosava G, Abdulkadyrov K, Hedenus M, et al. Randomized, double-blind, placebo-controlled trial of recombinant human erythropoietin, epoetin beta, in hematologic malignancies. J Clin Oncol 2002; 20: 2486-94.
25. Littlewood TJ, Bajetta E, Nortier JW, Vercammen E, Rapoport B; Epoetin Alfa Study Group. Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: Results of a randomized, doubleblind, placebo-controlled trial. J Clin Oncol 2001; 19: 2865-74.
26. Rodríguez JN, Diéguez JC, Muñiz R, Martino ML, Fernández-Jurado A, Amian A, et al. Eritropoyetina recombinante humana en el tratamiento de la anemia de los síndromes mielodisplásicos. Estudio metaanalítico. Sangre 1994; 39: 435-9.